US FDA Accepts Uganda’s Dei BioPharma’s Application for Diabetes and Weight Loss Drug
The U.S. Food and Drug Administration (FDA) has accepted an Abbreviated New Drug Application (ANDA) from Uganda’s Dei BioPharma for liraglutide, a multibillion-dollar treatment for diabetes and weight loss, marketed under the brand name Victoza. The FDA’s decision, officially recorded on April 23, 2025, clears a path for Dei BioPharma
